What MannKind and JR Automation Built
MannKind Corporation makes Afrezza, an ultra-rapid-acting inhaled insulin. The product delivers insulin through the lungs using a handheld inhaler instead of a needle, built on MannKind's own Technosphere drug-delivery platform. Afrezza pairs a dry insulin powder cartridge with that inhaler, which makes it a drug-device combination product. Every unit that ships has to be a matched, verified pairing of a pharmaceutical formulation and a mechanical delivery device.
As Afrezza demand grew, MannKind needed to raise assembly output at its manufacturing plant in Danbury, Connecticut, without loosening the consistency a drug-device product demands. The company brought in JR Automation, a Hitachi Group company and industrial robotics systems integrator, to design and build the automated assembly line.
JR Automation is not a robot manufacturer. Like most systems integrators, it builds production cells around robot arms sourced from established robotics vendors. It then adds the fixtures, vision systems, conveyors, and software that turn a bare arm into a working assembly station. The gap between a robot maker and an integrator matters for any pharmaceutical manufacturer evaluating automation. The robot arm itself is a commodity component. The integration work has to satisfy a regulator, and it usually accounts for most of the engineering hours and most of the project cost.
The resulting line handles the repetitive, high-precision steps of Afrezza cartridge and inhaler assembly at a volume and consistency level manual assembly could not sustain shift after shift. MannKind has continued running production on that automated line since the initial rollout, a sign the system held up under years of real manufacturing rather than a one-time pilot.
Why This Differs from a General Industrial Assembly Cell
A robotic cell assembling automotive brackets or consumer electronics answers to one standard: does the finished part meet spec. A robotic cell assembling a drug-device product answers to that standard plus a second, stricter one. It has to prove, to a regulator's satisfaction, that every single unit was made under the exact validated conditions the process was approved for.
That second standard changes what the automation has to do, not just how well it has to do it.
- Cleanroom-rated hardware. Robots, conveyors, and fixtures in a pharmaceutical cell typically run inside a cleanroom classified under International Organization for Standardization (ISO) standard 14644-1. That commonly means ISO Class 7 or ISO Class 5, depending on the process step, and the classification caps the particle count in the air around the product. Motors, cabling, and lubricants all have to be selected or shielded to avoid shedding particles into that environment, a constraint a general-purpose industrial cell never has to design around.
- Validated, not just tested. A general industrial line gets tuned until output looks right. A pharmaceutical line has to complete formal Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) instead. That process generates a paper and electronic record proving the equipment does what it was built to do, every time, before it may run a single commercial batch.
- Serialized, unit-level traceability. Under the Drug Supply Chain Security Act (DSCSA), every package has to carry a unique product identifier tied to lot number and expiration date. An automated line has to capture and record that identity at the point of assembly, not bolt on tracking after the fact.
- Change control with teeth. In general manufacturing, swapping a gripper or updating a vision algorithm is a maintenance task. Under FDA cGMP, the same change can trigger a formal requalification of the affected equipment before it may run product again. The original validation only covers the exact configuration it was tested against.
The Validation Burden Most General Robotics Guidance Skips
The single biggest operational difference in pharmaceutical robotic assembly is the requalification burden, and it applies to hardware and software alike. Changing the end-of-arm tooling, updating a vision-inspection model, or moving a sensor by two centimeters can send the equipment back through requalification before it touches product again. A general industrial line that fails a part check just gets recalibrated and restarted.
That burden is why pharmaceutical integrators build in more upfront engineering time than a comparable general-industry project needs. A general industrial line that fails a quality check gets recalibrated the same day. A pharmaceutical line facing the same failure can lose far more. An under-validated change risks more than a missed defect: it can put an entire production run out of compliance, a cost far larger than a scrapped part.
A pharmaceutical manufacturer should scope and price automation with requalification built in from day one, not as an add-on discovered after the line is running. An integrator quoting a pharmaceutical cell at the same cost structure as a general assembly cell has likely underscoped the validation work.
What to Ask an Integrator Before Automating a Pharma Line
A pharmaceutical manufacturer evaluating a robotic assembly project should treat the integrator selection as a compliance decision as much as an engineering one.
- Which cleanroom classification does the cell need to operate in, and does the integrator's proposed hardware, robot arm, conveyor, fixture materials, already carry documentation suitable for that class?
- What does the Installation, Operational, and Performance Qualification package look like? Is it built by the integrator or left to the manufacturer's own quality team afterward?
- How does the line capture and record the serialized identifier required under the Drug Supply Chain Security Act, and at what point in the assembly sequence does that capture happen?
- What triggers a requalification after go-live, a tooling swap, a software update, a sensor replacement, and how is that documented so an FDA inspector can trace it?
- Has the integrator built and validated a comparable drug-device or pharmaceutical assembly line before, versus only general industrial or automotive cells?
Who This Level of Diligence Does Not Fit
This validation-heavy diligence does not fit a company automating packaging or assembly for a non-regulated consumer or industrial product. General industrial automation guidance already covers that case, and cleanroom class or requalification triggers do not apply.
It also matters less for a pharmaceutical manufacturer that outsources production entirely to a contract manufacturing organization already holding validation ownership under contract. The requirements shift further if a manufacturer's product moves from a solid-dose or capsule line to an aseptic fill-finish process. Aseptic operations add sterility assurance requirements beyond what a dry-powder or tablet line like MannKind's needs to satisfy.
Outcomes at Production Scale
The measurable outcome of the MannKind and JR Automation project is sustained output. MannKind has run Afrezza assembly on the automated line for years past the initial rollout. The Danbury facility has since taken on manufacturing for a second inhaled product, Tyvaso DPI, marketed by United Therapeutics, on the same production infrastructure.
That longevity is the strongest evidence for any pharmaceutical manufacturer weighing automation: years of continuous, compliant production, not a single rollout announcement. A general industrial cell earns its return by cutting cycle time or scrap. A pharmaceutical cell earns its return the same way, but only after it clears a validation bar that decides whether it can run commercial product at all. A line that cannot clear that bar produces no output to measure.
Bottom Line
MannKind's automated Afrezza line, integrated by JR Automation, shows what pharmaceutical robotic assembly actually requires beyond a working robot arm. It needs a cleanroom-rated cell and a completed IQ/OQ/PQ validation package. It also needs serialized unit tracking under the Drug Supply Chain Security Act and a change-control process that can trigger requalification on a single tooling swap. General industrial robotics guidance rarely covers that last point, and it usually determines a pharmaceutical automation project's real cost and timeline.
Before selecting an integrator for a pharmaceutical assembly line, ask for a validated project reference at your required cleanroom class and a written requalification protocol, not just a robot demo.
FAQs
What does MannKind Corporation manufacture?
MannKind Corporation makes Afrezza, an ultra-rapid-acting inhaled insulin delivered through a handheld inhaler using the company's Technosphere drug-delivery platform. Its Danbury, Connecticut facility also manufactures Tyvaso DPI, an inhaled lung-disease treatment marketed by United Therapeutics.
Is JR Automation a robot manufacturer?
No. JR Automation, a Hitachi Group company, is a systems integrator. It designs and builds production cells around robot arms sourced from established robotics vendors. It then adds the fixtures, vision systems, conveyors, and validation work that turn a bare arm into a compliant pharmaceutical assembly line.
Why does pharmaceutical robotic assembly cost more than general industrial automation?
Pharmaceutical assembly cells have to meet ISO cleanroom classifications and complete Installation, Operational, and Performance Qualification under FDA cGMP. They also have to record serialized unit-level identifiers under the Drug Supply Chain Security Act. A general industrial cell answers to none of those requirements, and the extra engineering and documentation work drives pharmaceutical automation's higher upfront cost.
What triggers requalification of a pharmaceutical robotic assembly line?
A change to the equipment's validated configuration can trigger requalification. New end-of-arm tooling, an updated vision-inspection model, or a relocated sensor can all require the affected station to go back through Operational and Performance Qualification. That has to happen before it may run commercial product again. General industrial equipment typically only needs recalibration for the same kind of change.
What is serialization under the Drug Supply Chain Security Act?
The Drug Supply Chain Security Act requires a unique product identifier at the package level, tied to lot number and expiration date. That identifier lets a prescription drug be traced through the supply chain back to its origin. An automated pharmaceutical assembly line has to capture that identifier at the point of assembly rather than adding it as a separate downstream step.